CSL eyeing acquisition candidate in Vifor Pharma
![Photo: Vifor Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13520404.ece/ALTERNATES/schema-16_9/doc7inuamw8ozp7fpxyltq.jpg)
The Swiss specialty pharmaceuticals company, Vifor Pharma, is up 15.6 percent at CHF 120 (USD 130,4) following news that Australian CSL wants to take over the Swiss firm, writes Bloomberg News, citing Australian Financial Reviews.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck Foundation portfolio company acquired for USD 230m
For subscribers
Vifor Pharma gets new CEO
For subscribers